Acquired Company
Chemomab completed its merger with Anchiano Therapeutics on March 16, 2021, and began trading on the Nasdaq Capital Market under the symbol CMMB on March 17, 2021.
Chemomab Therapeutics Ltd. is a Tel Aviv-based clinical-stage biopharmaceutical company dedicated to developing innovative biological therapies aimed at inflammatory and fibrotic diseases. The company’s leading candidate, CM-101, is a monoclonal antibody that targets critical pathways involved in fibrosis, presenting significant potential for treating various conditions. Utilizing its proprietary technology platform, Chemomab is committed to addressing substantial unmet medical needs, thereby enhancing patient outcomes and quality of life. The company's strategic emphasis on pioneering health solutions positions it favorably within the competitive biopharmaceutical arena, making it an attractive prospect for institutional investors. Show more
Location: BUILDING 7, TEL AVIV-YAFO, ISRAEL, 6158002, Tel Aviv-Yafo, 6158002, USA | Website: https://www.chemomab.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
9.54M
52 Wk Range
$1.52 - $8.76
Previous Close
$1.57
Open
$1.62
Volume
22,134
Day Range
$1.55 - $1.64
Enterprise Value
-392.5K
Cash
6.974M
Avg Qtr Burn
N/A
Insider Ownership
14.06%
Institutional Own.
11.84%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nebokitug Details Primary Sclerosing Cholangitis | Phase 2 Update |